Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome

Abdellatif, Mohamed; Davis, Peter G; Wheeler, Kevin; Paoli, Antonio G De; Dargaville, Peter A.

doi:10.1002/14651858.cd011672.pub2

Cited by 99 publications

(106 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A meta-analysis found LISA to be associated with lower BPD incidence at 36 weeks' PMA and the incidence of the composite outcome of death or BPD at 36 weeks' PMA compared to conventional surfactant administration via intubation ( 44 ). Similar results were noted in the recent Cochrane review by Abdel-Latif et al (BPD-relative risk (RR): 0.57; 95% CI: 0.45–0.74; death-RR: 0.63; 95% CI: 0.47–0.84; combined BPD or death-RR: 0.59, 95% CI: 0.48–0.73) ( 45 ).…”

Section: Medications Used In Bpdsupporting

confidence: 86%

Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

Sakaria

Dhanireddy

2022

Front. Pediatr.

View full text Add to dashboard Cite

Bronchopulmonary Dysplasia (BPD) is a multifactorial disease affecting over 35% of extremely preterm infants born each year. Despite the advances made in understanding the pathogenesis of this disease over the last five decades, BPD remains one of the major causes of morbidity and mortality in this population, and the incidence of the disease increases with decreasing gestational age. As inflammation is one of the key drivers in the pathogenesis, it has been targeted by majority of pharmacological and non-pharmacological methods to prevent BPD. Most extremely premature infants receive a myriad of medications during their stay in the neonatal intensive care unit in an effort to prevent or manage BPD, with corticosteroids, caffeine, and diuretics being the most commonly used medications. However, there is no consensus regarding their use and benefits in this population. This review summarizes the available literature regarding these medications and aims to provide neonatologists and neonatal providers with evidence-based recommendations.

show abstract

Section: Medications Used In Bpdsupporting

confidence: 86%

Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

Sakaria

Dhanireddy

2022

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…Multiple studies have interrogated thin catheter administration of surfactant. A Cochrane review concluded that the thin catheter method was superior to endotracheal tube surfactant administration 3 . However, the majority of included studies enrolled subjects of GA >28 weeks at low risk of developing BPD.…”

Section: Commentarymentioning

confidence: 99%

EBNEO Commentary: OPTIMIST‐ically moving towards targeted noninvasive surfactant therapy?

2022

View full text Add to dashboard Cite

“…It was found that the LISAtreated infants scored higher on the psychomotor development index (PDI) and mental development index (MDI) [125]. With the recently published Cochrane review, in which the administration of surfactant via thin catheter compared with the administration via an endotracheal tube was found to significantly reduce the risk of death or BPD, intubation in the first 72 h of life, severe IVH, BPD in survivors as well as in-hospital mortality [126], and the pending results of the OPTIMIST-A trial, it is anticipated that the clinical use less invasive surfactant administration will be expanded.…”

Section: Less Invasive Surfactant Administration/minimal Invasive Surfactant Techniquementioning

confidence: 99%

The Intertemporal Role of Respiratory Support in Improving Neonatal Outcomes: A Narrative Review

et al. 2021

View full text Add to dashboard Cite

Defining improvements in healthcare can be challenging due to the need to assess multiple outcomes and measures. In neonates, although progress in respiratory support has been a key factor in improving survival, the same degree of improvement has not been documented in certain outcomes, such as bronchopulmonary dysplasia. By exploring the evolution of neonatal respiratory care over the last 60 years, this review highlights not only the scientific advances that occurred with the application of invasive mechanical ventilation but also the weakness of the existing knowledge. The contributing role of non-invasive ventilation and less-invasive surfactant administration methods as well as of certain pharmacological therapies is also discussed. Moreover, we analyze the cost–benefit of neonatal care-respiratory support and present future challenges and perspectives.

show abstract

Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome

Abstract: Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome (Review)

Cited by 99 publications

References 78 publications

Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

EBNEO Commentary: OPTIMIST‐ically moving towards targeted noninvasive surfactant therapy?

The Intertemporal Role of Respiratory Support in Improving Neonatal Outcomes: A Narrative Review

Contact Info

Product

Resources

About